Indication: newly diagnosed or recurrent; combo with active agents
Title: Glioblastoma (newly diagnosed or recurrent; combo with active agents) | XPORT-GBM-029
Drug: selinexor

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Early StageMid StageLate StageCommercial
Early Stage
Mid Stage
Late Stage
Commercial